# Admit Therapeutics S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/admit-therapeutics-s-l

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.admit-therapeutics.com/
- Total disclosed funding: $0.2M
- Latest round: Seed (Mar 19, 2019)
- Investors on record: 3

## About

Founded in 2017 and based in Barcelona, Spain, Admit Therapeutics, S.L. is a spin off from the Bellvitge Biomedical Research Institute that develops diagnostic technology based on an epigenetic analysis of blood samples that covers the analysis of many methylcytosines in mtDNA by next-generation sequencing. Marta Barrachina (CEO), Jordi Gascón, and Ramon Reñé are the co-founders of the company. In October 2023, Admit Therapeutics S.L. raised EUR 5.4 million in venture funding led by Clave Capital, including Lavanda Ventures Ltd., the Alzheimer's Drug Discovery Foundation, WA4Steam, the European Innovation Council, and the Ship2B Foundation.

The company’s primary product is a diagnostic test designed to identify Alzheimer’s disease at its earliest stages. This test utilizes epigenetic analysis of blood samples, where it examines many methylcytosines in mitochondrial DNA (mtDNA) through next-generation sequencing. This approach is based on the premise that systemic mitochondrial dysfunction occurs before the formation of cerebral abnormal protein aggregates. Admit Therapeutics focuses on epigenetic markers, offering several advantages such as early detection, non-invasiveness, and analysis. Some of the company’s partners include Eit Health, Bellvitge, KnightADRC, Cita Alzheimer, Aibl, and others.

The organization plans to use the October 2023 funding to expand its marketing of MAP-AD technology in Europe and the US.

## Funding rounds

- Seed, Mar 19, 2019, $0.2M — Banco Sabadell, Ship2B Foundation, Genesis Biomed

## Investors

- Banco Sabadell — Seed
- Ship2B Foundation (https://capitalatlas.ai/funds/ship2b-foundation) — Seed
- Genesis Biomed (https://capitalatlas.ai/funds/genesis-biomed) — Seed